The Children’s Tumor Foundation (CTF) is the drug discovery engine for NF. Everything we do is to bring treatments to patients as we work toward a cure. By connecting patients, doctors, scientists, and pharma, we drive treatments, advance care, and deliver results for millions affected by neurofibromatosis or schwannomatosis, collectively referred to as NF. Our patient-first approach accelerates drug development and brings life-changing therapies to patients faster, driven by our mission to end NF.
NF refers to a group of genetic conditions that cause tumors to grow on nerves throughout the body. NF affects 1 in 2,000 births and may lead to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, or cancer. NF affects all races, ethnic groups, and genders equally. NF includes neurofibromatosis type 1 (NF1) and all types of schwannomatosis (SWN), including NF2-related schwannomatosis (NF2-SWN), formerly called neurofibromatosis type 2 (NF2).
Shared 6 days ago
115 views
Shared 6 days ago
17 views
Shared 6 days ago
52 views
Shared 6 days ago
22 views
Shared 6 days ago
28 views
Shared 6 days ago
15 views
Shared 6 days ago
24 views
Shared 6 days ago
37 views
Shared 6 days ago
17 views
Shared 6 days ago
27 views
Shared 6 days ago
49 views
Shared 6 days ago
9 views
Shared 6 days ago
30 views
Shared 6 days ago
28 views
Shared 6 days ago
16 views
Shared 6 days ago
69 views
Shared 6 days ago
43 views
Shared 6 days ago
17 views
Shared 6 days ago
62 views
Shared 6 days ago
6 views
Shared 1 month ago
49 views
Shared 1 month ago
82 views
Shared 2 months ago
150 views
Shared 3 months ago
47 views
Shared 3 months ago
268 views
Shared 3 months ago
497 views
Shared 4 months ago
93 views
Shared 4 months ago
378 views
Shared 5 months ago
357 views
Shared 6 months ago
170 views
Shared 6 months ago
44 views
Shared 7 months ago
91 views
Shared 7 months ago
135 views
Shared 7 months ago
94 views
Shared 7 months ago
62 views
Shared 8 months ago
66 views
Shared 8 months ago
235 views
Shared 8 months ago
935 views